Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status.

Abstract

Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, the efficacy and safety of this treatment has not been compared between patients who possess epidermal growth factor receptor (EGFR) mutations and patients with wild-type EGFR. The objective of the present study was to evaluate the effect of the presence of EGFR gene mutations in patients with LA-NSCLC receiving cCRT. Between January 2007 and December 2013, the records of 64 patients were reviewed retrospectively. The data were statistically analyzed to evaluate the efficacy of cCRT according to EGFR mutation status. In total, 15/64 were revealed to possess EGFR mutations, 23%, and comprised the mutant EGFR group. The progression-free survival time was significantly shorter in the mutant EGFR group compared with the patient group with tumors exhibiting wild-type EGFR, 6.3 and 9.5 months, respectively (P<0.001). The overall survival rate was longer in the mutant EGFR group compared with the wild-type EGFR group, although the difference was not statistically significant, 37.1 and 21.1 months, respectively (P=0.26). The disease recurred in all of the patients of the mutant EGFR group, whilst the recurrence rate in the wild-type EGFR group was 89%. The frequency of distant metastasis was significantly higher in the mutant EGFR group compared with the wild-type EGFR group. In conclusion, these data suggest that additional studies are required to identify strategies for reinforcing the efficacy of cCRT, with a focus on the potential use of EGFR tyrosine kinase inhibitors for patients exhibiting an EGFR mutation.

• Authors: Mikiko Ishihara, Satoshi Igawa, Jiichiro Sasaki, Sakiko Otani, Tomoya Fukui, Shinichiro Ryuge, Ken Katono, Yasuhiro Hiyoshi, Masashi Kasajima, Hisashi Mitsufuji, Masaru Kubota, Masanori Yokoba, Masato Katagiri, Akane Sekiguchi, Itaru Soda, Hiromichi Ishiyama, Kazushige Hayakawa, Noriyuki Masuda
• Journal: Oncology letters (Oncol Lett) Vol. 14 Issue 1 Pg. 885-890 (Jul 2017) ISSN: 1792-1074 [Print] Greece
• PMID: 28693247 (Publication Type: Journal Article)